Hospital de Amor de Barretos

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Head and neck cancer2 trials
• Lung cancer2 trials
• Brain metastases1 trial
• Cervical cancer1 trial
• Colorectal cancer1 trial
• HIV1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 25 trials

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting1 trial

Lead sponsor

• Latin American Cooperative Oncology Group6 trials
• Stemline Therapeutics, Inc.1 trial
• Vyriad, Inc.1 trial

Running trials

• Recruiting

  A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

  NCT06822543· Phase 2· Latin American Cooperative Oncology Group· Source

  Contact: Flávio Augusto Ferreira da Silva (principal investigator)

• Active, not recruiting

  A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

  NCT05857397· Latin American Cooperative Oncology Group· Source

• Active, not recruiting

  ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

  NCT05596409· Phase 2· Stemline Therapeutics, Inc.· Source

• Active, not recruiting

  Epidemiological Landscape of Cervical Cancer in Latin America

  NCT04947605· Latin American Cooperative Oncology Group· Source

• Active, not recruiting

  Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  NCT04291105· Phase 2· Vyriad, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Brain metastases1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

  NCT05328765· Latin American Cooperative Oncology Group· Source

• Completed

  Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

  NCT05299125· Phase 2· Latin American Cooperative Oncology Group· Source

• Completed

  Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

  NCT04943445· Phase 2· Latin American Cooperative Oncology Group· Source